Becton, Dickinson and Co ( (BDX) ) has released its Q2 earnings. Here is a breakdown of the information Becton, Dickinson and Co presented to its investors.
Becton, Dickinson and Co. (BD) is a leading global medical technology company that specializes in medical devices, laboratory equipment, and diagnostic products, serving healthcare institutions and researchers worldwide.
In its second quarter fiscal 2025 earnings report, BD reported a revenue increase to $5.3 billion, marking a 4.5% rise from the previous year. The company also highlighted its strategic investments and product innovations, despite facing a challenging operating environment.
Key financial metrics from the report include a GAAP diluted EPS of $1.07 and an adjusted diluted EPS of $3.35, reflecting a 5.7% increase year-over-year. BD’s revenue growth was driven by its BD Medical segment, which saw a 12.7% increase, while the BD Life Sciences and BD Interventional segments experienced slight declines. The company announced a $2.5 billion investment in U.S. manufacturing capacity over the next five years, emphasizing its commitment to innovation and market leadership.
BD’s management remains optimistic about the future, updating its full-year fiscal 2025 guidance with expected revenues between $21.8 billion and $21.9 billion. The company anticipates adjusted diluted EPS growth of 7.0% to 9.1%, despite potential impacts from tariffs and foreign currency fluctuations. BD continues to focus on operational excellence and strategic investments to drive long-term growth.